TrialGynecologic oncology2018

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Bradley J Monk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.